How to Keep a Job With Crohn's Disease

Most people with Crohn's disease keep working. That is the first thing worth saying, because the question is usually asked from inside a bad week, and a bad week is a terrible vantage point from which to estimate the rest of your working life.

The second thing worth saying is that the numbers you will find to reassure or frighten yourself are much less solid than they look. Depending on which study you open, the share of people with Crohn's disease on some form of work disability is 6%, or 19%, or 27%, or 29%. Those studies were not measuring different diseases. They were measuring different populations in different benefit systems using different definitions, and almost every page that quotes one of them quotes it alone.

This guide does something the workplace-tips articles do not. It goes to the cohort studies to find out what actually separates the people who stay in work from the people who do not, and then builds the practical advice out of that, rather than out of a generic list of accommodations that would read the same for any condition.

The numbers on Crohn's and work disagree with each other, badly

If you search for how many people with Crohn's disease can work, you will be handed a confident percentage. Here are five of them, from five real studies, and they do not agree.

Three things explain most of that spread, and none of them is "Crohn's disease got better or worse."

Where the patients came from. The 29% figure comes from eight university medical centres, which is where the hardest disease is managed. The 5.8% figure comes from everyone diagnosed in a defined geographical area in a two-year window, easy cases included. Tertiary referral centres see a sicker sample by construction. That is not a criticism of the study, it is a reason not to read its percentage as the prevalence in everyone with Crohn's.

What counts as disabled. Dutch work disability is a graded benefit with partial categories; Norwegian disability pension is a different instrument; Brazilian records distinguish temporary aid from disability retirement. Comparing them is comparing administrative categories, not health states.

When the clock started. The Danish figure is seven years from diagnosis in a cohort diagnosed in the mid-2000s. The Dutch biobank figure is a snapshot of people with a mean disease duration long enough for complications to accumulate. Time in the disease matters: in the COIN survey, Crohn's disease duration over 15 years was among the factors associated with work disability (Spekhorst 2017).

That reframing changes what you should plan for. Almost all of the practical advice below is about absence management, energy management and predictability, because that is where the data says the pressure actually lands.

What the cohorts say predicts losing work

Across five independent cohorts, the same handful of factors keep reappearing, and the list is notably short on things that happen at the office.

• Disease activity. In the Swiss IBD Cohort Study of 1,187 patients, disease activity was the only predictor of permanent work disability in the whole group. For temporary work disability in Crohn's disease specifically, the model also picked up sex, disease duration, C-reactive protein, smoking, depressive symptoms, fistulas, extraintestinal manifestations and use of immunosuppressants or steroids (Siebert 2013).
• Markers of a severe early course. In IBSEN, steroid treatment at the one-year follow-up predicted work disability ten years later, in both Crohn's and colitis (Hoivik 2013). Needing steroids early is a marker, not a cause, but it is a marker worth taking seriously.
• Penetrating disease and previous surgery. Both appeared in the COIN analysis, alongside higher age, low education, depression, chronic back pain and joint manifestations (van der Valk 2014).
• Extraintestinal manifestations. Associated with work disability in all IBD patients in the Dutch biobank analysis (Spekhorst 2017). The people whose joints, eyes or skin are also involved are carrying more than a gut problem into work.
• Education level. Lower educational level was independently associated with long-term full work disability in Crohn's disease, with an odds ratio of 1.62 (Spekhorst 2017). This is not about intelligence. It is about how much room a job has to bend. A desk role can absorb a bad morning; a production line cannot.

Notice what is missing from that list: your manager's personality, your commute, the number of toilets on your floor. Those things matter enormously to how a given week feels, and the cohorts were not designed to measure them. But the variables the studies could measure point in one direction, which is that getting and keeping the disease quiet is the most powerful workplace intervention available, and it happens in the clinic rather than at your desk.

This is also the logic behind the shift in IBD care towards treating to objective targets rather than to how you feel. A review of disability prevention in IBD makes the case explicitly: the treatment paradigm moved from symptom control towards full control of disease, with preventing organ damage and disability as the point (Allen 2017). If your symptoms are settled but your inflammatory markers are not, that gap matters for your working life and not just your next scope, which is the subject of our guide on a high calprotectin with no symptoms.

The symptom that costs the most working hours is fatigue

Ask a room of people with Crohn's disease what makes work hard and the first answer is rarely the bathroom. It is being tired in a way that sleep does not touch. In the r/CrohnsDisease thread from someone questioning whether they could work at all, the description was fatigue, exhaustion and brain fog, not urgency (r/CrohnsDisease thread).

Here is where you have to be careful with the literature, because the prevalence figures for fatigue in IBD are all over the place and the reason is entirely methodological.

• A 2025 review puts it at "around half" of patients, higher in active disease than remission (Giri 2025).
• A Spanish day-hospital study of 422 patients, most of them in clinical remission, found 70.1% (Herrera 2026).
• A Saudi tertiary-centre study of 286 patients using the Brief Fatigue Inventory found 23.1% mild, 36.4% moderate and 19.2% severe, so roughly four in five reporting something and just over half reporting at least moderate fatigue (Mukhtar 2026).
• A Mexican study of 109 patients reported 94%, but it counted a score of 1 or more on both sections of its questionnaire as fatigue (Carrillo Rojas 2026). At that threshold, almost any tired person qualifies.

The honest summary is that fatigue is very common, that the exact percentage tells you more about the questionnaire than about the disease, and that you should not let a stray statistic do your thinking for you. What is more useful is the finding that keeps showing up regardless of instrument: fatigue persists in people whose disease is in remission. Most of the Spanish cohort were in clinical remission and 70% were still fatigued.

Two other threads are worth pulling. In the Mexican study, depression was the only independent predictor of fatigue severity (Carrillo Rojas 2026), and in the multicentre European study, patients with a depression or anxiety diagnosis had lower presenteeism, more sedentary lifestyles and higher unemployment (Sciberras 2022). Anxiety and depression are common in IBD: pooled prevalence of anxiety symptoms was 32.1% across 58 studies in a meta-analysis of 30,118 patients (Barberio 2021). If fatigue is what is threatening your job, the mood question is not a side issue, it is part of the same question.

Iron deficiency anaemia is the other treatable contributor that routinely goes unchecked. It is common in IBD because of chronic blood loss and impaired absorption, and intravenous formulations are the ones with the better evidence base in this population: in a network meta-analysis of five randomised trials in 1,143 patients, only ferric carboxymaltose was significantly more effective than oral iron (Aksan 2017), and a German post-marketing study in 224 IBD patients found the same formulation effective in routine practice (Stein 2018). That is not a recommendation to take anything, and iron is not a supplement to start on your own. It is a reason to ask your IBD team whether your ferritin and haemoglobin have been checked recently, if you are exhausted at work and nobody has looked.

For the fatigue that is left after inflammation and anaemia have been addressed, the trial evidence is thin and small. A randomised pilot in 29 people with quiescent Crohn's disease and high fatigue scores compared problem-solving therapy, solution-focused therapy and treatment as usual: fatigue scores improved in 85.7% of the solution-focused group, 60% of the problem-solving group and 45.5% of the usual-care group, and neither quality-of-life difference reached significance (Vogelaar 2011). Twenty-nine people split three ways is a pilot, and the authors framed it as one. Treat it as a reason to ask about psychological support for fatigue, not as proof that it works.

Presenteeism: the cost your employer never sees

Absence is visible and gets managed. Being at work while your body is elsewhere is invisible and gets nothing, which is why it is the more dangerous of the two for a career.

In a multicentre study of 585 IBD patients, all in clinical remission, 34.0% scored in the low-presenteeism range on the Stanford Presenteeism Scale (Sciberras 2022). Not on sick leave. Not flaring, by the clinical definition. At work, and not working well.

The Finnish costing study makes the scale concrete. In 320 employed IBD patients, mean annual productivity-loss costs were 643.90 euros per patient for presenteeism and 740.90 euros for absenteeism (Rankala 2021). Those two numbers are close to each other, which is the point: roughly half of the lost productivity never appeared as a day off. The same study found women had higher absenteeism costs than men, 955 euros against 531 euros per year, with the difference most pronounced in blue-collar work.

For women who notice their worst work weeks arriving on a schedule, our guide to why Crohn's gets worse around your period covers the cyclical pattern and what is actually documented about it. Predictable bad days are far easier to build a rota around than random ones.

Brain fog at work, and what the cognition studies actually show

"My brain doesn't work the same anymore" is a recurring post title in r/CrohnsDisease, and it is one of the few workplace complaints that now has prospective data attached, though less than the internet implies.

In a study of 356 adults aged 60 and over with IBD across six American centres, 42% screened positive for cognitive impairment on the Montreal Cognitive Assessment at baseline, with delayed recall and visuospatial function the most affected domains. After adjusting for age, race, education, depression, comorbidities, IBD type, duration and baseline score, symptomatically active IBD at baseline was associated with worsening cognitive testing within a year, with an adjusted odds ratio of 3.01 (Kochar 2026).

That is a real finding, and it needs three caveats stated at the same volume. The population was 60 and over, so it does not transfer cleanly to a 28-year-old struggling to concentrate in meetings. The exposure was symptomatically active disease, which is not the same as endoscopic inflammation. And a screening instrument is not a diagnosis.

A second prospective study is more sobering about how hard this is to measure. Forty IBD patients and 42 controls undergoing colonoscopy were given a tablet-based cognitive assessment plus EEG monitoring during the procedure. After adjustment, EEG alpha power did not differ between groups. Both groups scored in a range indicating moderate likelihood of cognitive impairment. The one difference was that controls improved on retesting six to eighteen months later and IBD patients did not (Raje 2026). The absent practice effect is interesting. It is also fifteen patients and seventeen controls at follow-up, in a group that was younger, more likely to screen positive for depression and had fewer years of education than the comparison group.

So: brain fog is not imaginary, the objective evidence for it is early and mostly in older or small samples, and the most consistent signal is that it tracks with active disease. For work, the practical implication is the boring one. If your concentration has changed, that is worth raising with your IBD team as a disease-activity question, not only with your manager as a performance question.

Build the plan around the parts that are predictable

Crohn's disease feels unpredictable, and much of it is. But a surprising share of the working time it consumes is scheduled weeks in advance, and that is the part an employer can plan around if you let them.

Infusions and their aftermath. One of the most upvoted replies in the thread about working with Crohn's described the disease's main effect on the job as infusion days, which wiped out the whole day and consumed paid time off, plus surgical recovery (r/CrohnsDisease thread). An infusion is a diary entry months ahead. So is the day after.

Procedures and preparation. A colonoscopy costs two days, not one, and the prep day is the one people forget to book. Being rostered on a twelve-hour customer-facing shift while drinking bowel prep is an avoidable collision. Our colonoscopy prep guide for Crohn's covers what that day actually involves.

Surgery, at the population level. The meta-analysis of population-based studies put the cumulative risk of surgery after a Crohn's diagnosis at 16.3% at one year, 33.3% at five years and 46.6% at ten years, with the risk decreasing over calendar time (Frolkis 2013). That is a population figure, not a prediction about you, and the downward trend is part of the finding. But it means a working life with Crohn's disease should be planned assuming that a block of leave may be needed at some point, rather than treating it as an emergency when it arrives.

Routine monitoring. Bloods, faecal calprotectin, clinic appointments and iron infusions are all schedulable. Batched into one morning, they are one absence. Scattered, they are four.

The reason this matters is that attendance policies almost always treat frequent short absences worse than one planned block. Moving as much of your care as possible from the first category into the second is one of the few genuinely mechanical wins available.

A schedule audit: four weeks, then one conversation

Here is the practical sequence that turns a diffuse "I'm struggling" into something a manager can act on.

Weeks one to four: log four fields, not twenty. Date and time, what the symptom was, what it stopped you doing at work, and how long the interruption lasted. Add any planned medical time. That is it. The point is not a clinical record, it is a map of where the working day breaks.

At the end of week four, count three things.

Then write one page, not a diary. Whatever your log says, the request is more likely to land if it is framed as a barrier and a proposed adjustment rather than as a medical history. Our sibling post on IBS accommodations at work sets out that request mechanic in full, including what a supporting letter should and should not say, and it applies just as well here, so this guide will not rebuild it.

A worked example. Someone with ileal Crohn's disease logs four weeks and finds: eleven hours lost between 8am and 10:30am to urgency and cramping, almost nothing after midday; six hours lost to two clinic appointments and a blood draw booked on separate days; and seven days where they were present but wrote off the afternoon because of fatigue. The resulting request is not "I need understanding." It is three specific things: a 10am core-hours start with the same finishing obligations, permission to batch monitoring appointments into one morning per quarter, and one home-working day placed on the day after infusions. Each one maps to a counted number.

Which jobs actually work better, and what the evidence cannot tell you

There is no study ranking occupations by how well they accommodate Crohn's disease. Anyone presenting a list as evidence-based is overselling it. What exists is a large amount of consistent community experience, and it is worth reporting honestly as exactly that.

In a thread asking which fields suit people with Crohn's, the most upvoted replies clustered tightly: software development and technology roles, for the remote options and self-managed time; accounting; writing and editing; public-sector and local-government employment, repeatedly recommended for sick-leave provision, union representation and job security rather than for the work itself (r/CrohnsDisease thread). The top reply in that thread was from a nurse saying plainly that nursing is not the career for Crohn's disease and arthritis.

The jobs that come up as hardest share a structure rather than an industry: you cannot leave the room at short notice, and someone is depending on you at that exact moment. Nursing, teaching, emergency services, the military, delivery driving and trades all recur. The thread titled "is there anything worse than a flare up at work" was posted by a nurse stuck in a bathroom with patients waiting, and the replies came from a resident, a middle-school teacher and a soldier (r/CrohnsDisease thread). A detail in that thread is worth flagging rather than admiring: more than one person described not eating or drinking during a shift to avoid needing the toilet. That is a coping strategy with a cost, and one of them described becoming lightheaded because of it.

The indirect evidence does point the same way as the community wisdom, weakly. Blue-collar work was associated with higher productivity-loss costs in the Finnish study (Rankala 2021), and lower education level with long-term work disability in the Dutch one (Spekhorst 2017). Neither is about the job title. Both are consistent with the idea that control over your own time is the thing that protects you.

Which leads to the most useful reframing in the whole area: the variable is not the industry, it is how much slack the role has. Two software jobs can differ more than a software job and a nursing job, if one is deadline-based with autonomy and the other is a monitored support queue with scheduled break windows. When you are assessing a role, the questions worth asking are about slack: how work is measured, whether hours are fixed or core, what the sick-leave policy actually says, and whether anyone else can cover an hour at no notice.

Disclosure is three decisions, not one

People agonise over "should I tell them," and the agony usually comes from collapsing three genuinely different choices into one.

Telling the organisation. HR, occupational health or a disability service. This is the route that produces formal, documented adjustments, and in most systems it is the one that starts the clock on legal protections. It is also the most impersonal, which is often an advantage.

Telling your line manager. This is the one that governs whether a bad Tuesday morning is a problem. Formal adjustments are worth having, but day to day it is the manager who decides whether you are treated as unreliable or as someone with a known condition and an agreed plan.

Telling colleagues. Entirely optional, and reversible only in one direction. Some people find it lifts an enormous weight; others find it changes how they are seen. If you do tell people, what not to say to someone with ulcerative colitis is a guide you can forward rather than explain from scratch.

On timing, the rules differ by country and the detail matters. In the United States, employers generally may not ask disability-related questions before making a job offer, which means an interview disclosure is a choice rather than an obligation. In the United Kingdom, employers must make reasonable adjustments so that workers with disabilities or health conditions are not substantially disadvantaged, and that duty extends to the recruitment process itself (GOV.UK). Again, our accommodations post sets out the mechanics in detail and there is no point restating them here.

What this guide can add is the evidence on what disclosure costs, because it is not zero and pretending otherwise is dishonest. In a survey of 4,670 European IBD patients, 24% reported receiving unfair comments about their work performance (Lonnfors 2014). In a study of 211 patients, 84% reported some perceived stigma, and perceived stigma accounted for between 10% and 22% of the variance in quality-of-life scores (Taft 2009). A follow-up study of 191 patients found 36% experienced internalised stigma, which related strongly to poorer outcomes, and 88% showed moderate to high stigma-resistance behaviours (Taft 2013).

Those are self-report studies in self-selected samples, and they measure perception rather than employer behaviour. But they say something the workplace-tips pages skip: the reluctance to disclose is not irrational timidity, it is a response to a real pattern. The practical conclusion is not "never tell anyone." It is that disclosure should be strategic, staged, and framed around what you need rather than what you have.

One thread in this space is worth handling carefully. In a widely read post, someone described being fired after repeated late arrivals caused by morning urgency, having disclosed the diagnosis at interview, and the replies were full of confident and contradictory legal assertions about ADA and FMLA coverage (r/CrohnsDisease thread). Some of those replies corrected themselves mid-comment. Reddit is where you find out you are not alone. It is not where you find out whether you have a case.

Leave, job protection and the part people do not know about

Two facts are worth having in hand before a difficult conversation, because both are frequently misunderstood in the threads.

Intermittent leave exists. Under the US Family and Medical Leave Act, eligible employees may take up to 12 workweeks of job-protected leave in a 12-month period for a serious health condition, and crucially they have the right to take it in separate blocks of time or by reducing daily or weekly hours when medically necessary, rather than all at once. Employers must continue group health coverage during it, and cannot count that leave against attendance points or use it as a reason for discipline or denied promotion (US Department of Labor). Eligibility is narrower than people assume: 12 months with the employer, 1,250 hours of service in the preceding 12 months, and a worksite with at least 50 employees within 75 miles. A new starter, as in the thread above, will usually not qualify yet, which is exactly the misconception that thread contained.

In the UK, there is funding your employer does not pay for. Access to Work can grant money towards practical support at work, including specialist equipment, support workers, and travel costs where public transport is not usable, and your workplace can include your home if you work from there. The grant does not affect other benefits and does not have to be repaid (GOV.UK). The important limit, stated on the same page, is that Access to Work will not pay for reasonable adjustments, because those are the changes your employer is already legally required to make. So it is a second lever, not a substitute for the first.

Beyond those, the ground rules vary far too much by country and contract to generalise. Phased return after surgery, disability-related absence being recorded separately from ordinary sickness, and adjusted attendance trigger points are all things that exist in many workplaces, and all things you have to ask about specifically. If you are considering longer-term disability support, that is a jurisdiction-specific question with strict criteria, and it belongs with an adviser who knows your system rather than with a health blog.

Does better treatment actually protect your job? The evidence disagrees with itself

This is where an article like this is supposed to say "get your disease under control and everything else follows." The honest version is more complicated, and the three best pieces of evidence point in different directions.

The systematic review says yes, in trials. A review of 30 non-interventional and 17 interventional studies concluded that biologic agents showed a positive effect on work absenteeism and presenteeism in randomised clinical trials, while the impact of surgical interventions needed further evaluation (Busch 2014).

The real-world costing study says no. In 320 employed Finnish IBD patients, the authors state plainly that the use of biologics did not have a major impact on presenteeism and absenteeism costs (Rankala 2021). This is a cross-sectional analysis, not a trial, and people on biologics have worse disease to begin with, which works against them in exactly this kind of comparison.

The industry-funded survey says yes, but compares the wrong groups. A US cross-sectional study drawing on a commercial physician-and-patient survey panel reported mean overall work impairment of 21.1% for patients on ustekinumab versus 51.0% for moderate-to-severe patients not on it, with presenteeism 19.8% versus 44.9% and annual productivity-loss cost 12,211 dollars versus 30,096 dollars. The Europe PMC record lists Janssen Scientific Affairs, which markets the drug, as the funder, and the author list includes people affiliated with the company (Ding 2025). Set the funding aside for a moment: the comparison group is defined as people with moderate-to-severe activity who are not on the drug, so the study is partly comparing controlled disease against uncontrolled disease and attributing the whole difference to one medicine. The work-productivity analysis rests on 39 patients per arm.

Taken together, the fair reading is: controlling inflammation plausibly helps your working life, the trial evidence supports that, the real-world evidence is weaker than the trial evidence, and the most quotable numbers come from the study with the most commercial interest in them. None of this is a reason to change anything you are taking. It is a reason to be sceptical of a page that tells you a particular drug will save your career.

There is also a distinction the productivity literature tends to blur, which our post on telling a Crohn's flare from something else goes into: symptoms and inflammation do not move in lockstep, in either direction. Feeling better does not always mean the disease is quiet, and feeling terrible does not always mean it is active.

"Am I weak for not being able to work?"

This question comes up constantly and every workplace-tips page ignores it, so it is worth answering directly.

Some people with Crohn's disease genuinely cannot work, and some who currently cannot will be able to later. In the thread from someone whose doctor had implied they should be working, the replies were split in a way that is itself informative: several people said most patients with Crohn's do work and that routine and purpose helped them, one said they had pushed through years of twelve-hour days, and others described being unable to drive five minutes without an accident (r/CrohnsDisease thread). All of those are true statements about different people with the same diagnosis.

The data supports that spread rather than resolving it. IBD-related disability, measured with a validated tool in 1,700 French and Belgian patients, was strongly associated with self-reported clinical activity, with perceiving a need for a psychotherapist, and with perceiving a need for a social worker (Tannoury 2021). That last one is a striking finding to sit with: the people who most needed practical, social and financial help were the most disabled, and it was measured as a perceived unmet need.

What is not supportable is the implication that whether you work is a measure of how hard you are trying. The cohorts measure disease activity, complications, surgery and extraintestinal manifestations, and those are not effort variables.

Day-to-day things that make a shift survivable

None of these are studied. They come from the threads, and they are offered as what people describe doing, not as advice with evidence behind it.

• Decide the escalation in advance. Who covers you, what you say, and at what point you go home. People who had settled those questions described the interruption as manageable; people deciding in the moment described panic.
• Keep a change of clothes where you work. This came up repeatedly and unglamorously, from people in offices, on wards and in vehicles.
• Know where the toilets are before you need them, including on the commute. Our post on travelling with IBS-D covers toilet-access schemes and cards, which apply equally to Crohn's disease and are worth having for a commute as much as a holiday. If a trip involves a plane, flying with Crohn's disease medication covers the supply and storage rules.
• Treat the commute as part of the working day. Several of the worst descriptions in these threads are not about work at all, they are about being stuck in traffic. A flexible start time solves a commute problem as often as it solves a bowel problem.
• Work socials are a separate problem. Drinks after work are a common flashpoint, both for symptoms and for disclosure. What alcohol does and does not do in Crohn's disease is covered in our guide on drinking with Crohn's.
• Eating at work during a bad patch is its own question, and the honest answer is not a food list. Our guide on what to eat during a Crohn's flare goes through it, including why nobody can hand you a definitive one.

If you want to turn four weeks of this into something a manager or an IBD nurse can read in two minutes, that is the specific job a tracker is good at. Clairop logs symptoms in seconds and produces a one-page summary for an appointment, which our page on how it works walks through. For what to hand over and how, our post on using a symptom tracker for your doctor covers which formats clinicians actually read.

Red flags: see a doctor promptly

Working through symptoms is normal with Crohn's disease. Working through these is not.

See a doctor promptly for: new or increasing blood in your stool, unexplained weight loss, fever, night-time symptoms that wake you, new or worsening anaemia, a new perianal lump, pain or discharge, symptoms that have changed character rather than just intensity, or symptoms starting for the first time after age 50. If you are on immunosuppressive treatment, a fever is a same-day call to your IBD team rather than something to sit out in a meeting.

Myths about Crohn's disease and work

"Most people with Crohn's end up unable to work." Not according to the population data. In the Danish inception cohort, unemployment rates were no different from matched controls after seven years (Vester-Andersen 2015). The elevated risks were for sick leave and work disability, and the work disability rate for Crohn's in that cohort, 5.8%, was described by the authors as markedly lower than previous studies had reported.

"29% of people with Crohn's are work disabled." That figure is real and it comes from eight university medical centres (Spekhorst 2017). Tertiary centres concentrate severe disease. Quoting it as the general rate is a category error, and it is quoted that way constantly.

"If you pick the right job, you will be fine." The cohorts do not measure job titles, and the variables they do measure are clinical: disease activity, steroid use early on, penetrating disease, surgery, extraintestinal manifestations (Siebert 2013; van der Valk 2014). A good job makes a hard disease survivable. It does not replace treatment.

"Remote work solves it." Remote work removes the commute and the toilet-access problem, which is a lot. It does nothing for fatigue, and the presenteeism data suggests fatigue is where roughly half the lost productivity sits (Rankala 2021). Several people in the threads also described remote work worsening the isolation and the sleep pattern.

"Telling your employer protects you automatically." Protection depends on which legal framework applies, whether you meet its definition, what you disclosed and to whom, and in the US whether you are eligible for FMLA at all, which a new starter usually is not (US Department of Labor). Disclosure is usually a necessary step. It is not a force field.

"Not eating on shift keeps the symptoms away." It is a common strategy in these threads and it carries real risks of dehydration and lightheadedness, particularly after bowel surgery. It is a sign the working pattern needs changing, not a technique to perfect.

The honest bottom line

Most people with Crohn's disease work, and the evidence says the threat to that is less about being unemployable and more about absence accumulating faster than an attendance policy expects. The factors that predict losing work are clinical: disease activity above all, plus complications, surgery, extraintestinal manifestations and the mood problems that travel with all of it. Fatigue and presenteeism cost at least as many working hours as toilet trips, and they are invisible to everyone but you.

What follows practically is unglamorous. Get the disease as quiet as your team can get it, and treat concentration changes and exhaustion as disease-activity questions rather than character flaws. Count four weeks of interruptions so that your request is made of numbers rather than adjectives. Move as much of your care as possible into planned blocks, because planned absence is treated better than scattered absence everywhere. Disclose deliberately and in stages. And when you are weighing up a job, look for slack, meaning control over your own time, rather than for an industry that someone on the internet said was safe.

Finally, hold both halves of this at once: most people with Crohn's disease can work, and some genuinely cannot, and which group you are in is not a statement about your character. If you are in the second group right now, that is a clinical situation to work on with your team and a practical one to get advice on, not a verdict.